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ideal target for anticancer drugs, the purpose of this study was to investigate whether clini-
cally acceptable colchicine concentrations have anticancer effects on gastric cancer cells,
and its possible anticancer mechanisms. Two human gastric cancer cell lines (i.e., AGS and
NCI-N87) were investigated by proliferative assay, microarray, quantitative reverse
transcriptase-polymerase chain reaction, and a nude mice study using clinically acceptable
colchicine concentrations (2 ng/mL and 6 ng/mL for in vitro tests and 0.07 mg colchicine/
kg/d for in vivo tests). Our results showed that colchicine had the same inhibitory effects
on the proliferation of both cell lines. The antiproliferative effects of colchicine on both cell
lines were achieved only at the concentration of 6 ng/mL (p < 0.0001). In both cell lines, 18
genes were consistently upregulated and 10 genes were consistently downregulated by 6 ng/
mL colchicine, compared with 2 ng/mL colchicine. Among these genes, only the upregulated
DUSP1 gene may contribute to the antiproliferative effects of colchicine on gastric cancer
cells. The nude mice (BALB/c-nu) experiment showed that colchicine-treated mice after
14 days of treatment had lower increased tumor volume ratios (pZ 0.0199) and tumor growth
rates (p Z 0.024) than the control mice. In conclusion, colchicine has potential for theeclare no conflicts of interest.
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high clinically acceptable colchicine concentrations. Monitoring the colchicine plasma concen-
tration is mandatory if this drug is applied for the palliative treatment of gastric cancer.
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Gastric cancer is a disease with one of the highest cancer
mortality. Surgical resection of all lesions is essential for
curative treatment. For patients with advanced gastric
cancer, many regimens of palliative chemotherapy have
been applied, but the results are modest [1e3]. Therefore,
a search for a new anticancer drug suitable for the pallia-
tive treatment of patients with advanced gastric cancer is
necessary.
Colchicine is a very cheap alkaloid agent that has been
used in medicine for a long time [4e7]. Colchicine is a
microtubule destabilizer that has very strong binding ca-
pacity to tubulin to perturb the assembly dynamics of mi-
crotubules [8e11]. Colchicine also can increase cellular free
tubulin to limit mitochondrial metabolism in cancer cells
through inhibition of the voltage-dependent anion channels
of the mitochondrial membrane [12]. The clinical applica-
tion of colchicine has been limited because of its toxicity,
although oral colchicine is a safe treatment when appro-
priately used and contraindications have been excluded
[4e7]. The peak plasma concentrations after oral adminis-
tration of 0.6e1 mg colchicine range approximately
2e6 ng/mL [13e15]. The lowest reported lethal dose of oral
colchicine is 7e26 mg, and an acute ingestion of colchicine
exceeding 0.5 mg/kg has a high fatality rate [7]. Our recent
study showed that clinically acceptable colchicine concen-
trations (i.e., 2e6 ng/mL) had potential for the palliative
treatment of hepatocellular carcinoma [16] and chol-
angiocarcinoma [17]. The antiproliferative effects of
6-ng/mL colchicine on hepatocellular carcinoma cells were
the same as 1 mg/mL epirubicin, which is near the maximum
plasma concentration of epirubicin obtained by an intrave-
nous bolus of 75 mg/m2 body surface epirubicin in patients
[18]. The purpose of this study was to investigate whether
clinically acceptable colchicine concentrations also had
anticancer effects on gastric cancer cells and its possible
anticancer mechanisms. All gene names are in accordance
with the official symbols from the HUGO Gene Nomencla-
ture Committee provided by the United States National
Center for Biotechnology Information (Bethesda, MD, USA).Materials and methods
Cell lines
Two human gastric cancer cell linesdAGS and NCI-
N87dpurchased from the American Type Culture Collection
(Rockville, MD, USA) were investigated. All cultures were
maintained at 37C in a humidified atmosphere of 5%carbon dioxide (CO2) and 95% air. The serum-containing
culture medium consisted of 10% fetal bovine serum, 90%
Dulbecco’s Modified Eagle’s high glucose medium, supple-
mented with 20mM L-glutamine, 100 units/mL penicillin,
and 100 mg/mL streptomycin (HyClone, Logan, Utah, USA).
Colchicine was purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Proliferative experiment
Each cell line was seeded in 96-well culture plate and
incubated with serum-containing medium for 48 hours. The
medium was then replaced with serum-free medium con-
taining various concentrations of colchicine (0 ng/mL, 2 ng/
mL, 6 ng/mL). The cells were further incubated for 72 hours
for the proliferative assay. The premixed WST-1 cell pro-
liferation reagent (Clontech Laboratories, Inc., A Takara Bio
Company, Mountain View, CA, USA) was applied. The prin-
ciple for this examination is that the stable tetrazolium
salt, WST-1, is cleaved to soluble formazan dye by viable
cells. The amount of formazan dye formed detected by
spectrophotometer (expressed as optical density) is
directly correlated with the number of metabolically active
cells in the culture. The experimental procedures were
performed by the manufacturer’s protocols. The cells were
incubated with reagent for 3 hours at 37C in a humidified
atmosphere of 5% CO2 and 95% air. The results were
thereafter analyzed by an automated microplate reader
(MRX; Dynex Technologies, Inc., Chantilly, VA, USA). The
absorbance was measured at the 450-nm wavelength. (The
reference wavelength was 630 nm.) In all experiments, 16
replicate wells were used for statistical calculation.
Microarray and quantitative reverse transcriptase-
polymerase chain reaction experiments
Each cell line was seeded in three 25-cm2 plastic culture
flasks with a serum-containing medium for 24 hours. The
medium was then replaced with serum-free medium con-
taining various concentrations of colchicine (i.e., 0, 2 ng/
mL, 6 ng/mL). The cells were further incubated for
24 hours. The total RNA in each flask was extracted by
Trizol Reagent (Invitrogen/Life Technologies Corporation,
NY, USA), and followed by RNAeasy Mini Kit (QIAGEN GmbH,
Hilden, North Rhine-Westphalia, Germany). Purified RNA
was quantified at optical density 260 nm by an ND-1000
spectrophotometer (Nanodrop Technology, Wilmington,
DE, USA) and qualified by a bioanalyzer (Bioanalyser 2100;
Agilent Technology, Santa Clara, CA, USA). Two microarrays
(Agilent SurePrint G3 Human GE 8  60 k; Agilent Tech-
nologies, Santa Clara, CA, USA) were applied to investigate
Figure 1. Antiproliferative effects of colchicine on two
gastric cancer cell linesdAGS and NCI-N87. The premixed WST-
1 cell proliferation reagent was applied for investigation. The
absorbance is measured at the 450-nm wavelength (reference
wavelength, 630 nm). In all experiments, 16 replicate wells
were used to determine the mean and the standard deviation.
The unpaired two-tailed t test was applied for statistical
analysis. Bars indicate the standard deviation (SD). (a)
p Z 0.5052; (b,c,e,f) p< 0.0001; and (d) p Z 0.0628. The
inhibitory effects of 6 ng/mL colchicine on cellular prolifera-
tion are 47.8% and 61.1% for the AGS cells and NCI-N87 cells,
respectively.
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6 ng/mL colchicine, compared with 2 ng/mL colchicine, in
both cell lines. Microarray experimental procedures were
performed according to the manufacturer’s protocols and
the criteria for the selection of differentially expressed
genes were the same as in our previous studies [19,20]. For
the quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) study, specific oligonucleotide primer
pairs were selected from the Roche Universal ProbeLibrary
(Roche Diagnostics Ltd., Taipei, Taiwan). The procedures
for RT-PCR reactions and the calculation of the fold
expression or repression of the target gene were the same
as in our previous studies [19,20]. The housekeeping gene
TATA box binding protein (TBP) was the reference gene.
Three genes were selected for the quantitative RT-PCR
study. The PCR primers were 50-ATCCGACTCCTGATTATG-
TATGGC-30 (sense primer) and 50-GCTATGCGA-
GAGGTCTTGTAGG-30 (antisense primer) for ANKRD1; 50-
CCGAGTTCCTCTGGGTTTCT-30 (sense primer) and 50-CAG-
CAAATGTCTTGACGCTAA-30 (antisense primer) for DUSP1,
50-GGTTTCTTCCAGCCACATTGAG-30 (sense primer) and 50-
TGAACTATCACAAAGCACTAAAGGG-30 (antisense primer) for
FHL2, and 50-CAATTTAGTAGTTATGAGCCAGAG-30(sense
primer) and 50-TTCTGCTCTGACTTTAGCAC-30 (antisense
primer) for TBP.
Nude mouse experiment
This study was approved by the Institutional Animal Care
and Use Committee of Kaohsiung Medical University
(Kaohsiung, Taiwan). All mice were maintained in the
Experimental Animal Center of our university. The feeding
process was performed by qualified staff using a syringe
connected to a feeder. Fourteen male nude mice (BALB/c-
nu) purchased from the Taiwan Laboratory Animal Center
of National Health Research Institutes (Zhunan Town,
Miaoli, Taiwan) were equally divided into the control group
and the two treatment groups. A total of 1  107 NCI-N87
cancer cells suspended in 0.2 mL fetal bovine serum were
injected subcutaneously into the flank of each mouse.
When tumors reached a diameter of 10 mm for the largest
dimension, each mouse in the treatment group was
continuously fed 0.07 mg colchicine/kg dissolved in
phosphate-buffered saline once daily for 14 days. All mice
were sacrificed on the 15th day after the start of colchicine
treatment. The tumor volumes were calculated by the
formula: length  width2  0.5 [21]. The increased tumor
volume ratio was calculated as follows: tumor volume at
day x (Vx) divided by the baseline pretreatment tumor
volume (V0) [22]. The tumor growth rates were calculated
by the formula: ln(V0  V14)/(t0  t14), in which V0 and V14
are the tumor volumes at the start of treatment and at the
14th day of treatment, respectively, and t is the day for the
measurement of the tumor volume [23].
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software, Version 4.03 (GraphPad Software, Inc., La Jolla,
CA, USA). The results are expressed as the mean value 
the standard deviation or the standard error of the mean.An unpaired two-tailed t test was used to analyze the sig-
nificance of any difference between two means. Statistical
significance was defined as p < 0.05.
Results
Proliferative experiment
Colchicine showed the same inhibitory effects on prolifer-
ation in both cell lines (Figure 1). The antiproliferative
effects of colchicine on both cell lines were achieved only
at the concentration of 6 ng/mL.
Microarray and quantitative RT-PCR analyses
Results of the microarray showed that colchicine at con-
centration of 6 ng/mL caused the upregulation of 50 genes
and 22 genes and the downregulation of 24 genes and 16
genes for the ASG cell line and NCI-N87 cell line, respec-
tively, compared with 2 ng/mL colchicine. Eighteen genes
(i.e., ANKRD1, CTGF, DUSP1, EDN1, FHL2, GBP1, KRT14,
KRT16P2, KRT17, KRT80, LOC145694, MYL7, NCF2, NPPB,
PHLDB2, SAMD4A, SERTAD4-AS1, TGFBI ) were consistently
upregulated and 10 genes (i.e., ACTRT2, MEIOB, C1QTNF5,
C9orf106, DUSP9, FZD9, MAGEE1, SPPL2B, TNXB, ZNF652)
were consistently downregulated by 6 ng/mL colchicine in
both cell lines (Table 1).
Table 1 Differential expressions of common genes induced by 6 ng/mL colchicine, compared with 2 ng/mL, in the ASG and
NCI-N87 cell lines.
Functional grouping Upregulation (n Z 18) Downregulation (n Z 10)
Related to cytoskeleton KRT14, KRT16P2, KRT17, KRT80, MYL7, PHLDB2 ACTRT2
Related to extracellular matrix TGFBI TNXB
Related to cytokine activity EDN1, GBP1
Related to growth factor CTGF
Related to hormone activity NPPB
Related to transmembrane signal transduction SPPL2B
Related to transcription ANKRD1, FHL2 ZNF652
Related to post-transcriptional regulation SAMD4A
Related to AMPK signaling pathway C1QTNF5
Related to MAPK signaling pathway DUSP1 DUSP9
Related to Wnt signaling pathway FZD9
Related to NADPH metabolism NCF2
Related to MAGE family MAGEE1
Related to meiosis MEIOB (C16orf73)
Unknown SERTAD4-AS1 (C1orf133), LOC145694 C9orf106
All gene names are in accordance with the official symbol from the HUGO Gene Nomenclature Committee.
AMPK Z adenosine monophosphate-activated protein kinase; MAPK Z mitogen activated protein kinase; NADPH Z reduced form of
nicotinamide adenine dinucleotide phosphate.
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detected by microarray, three genes (i.e., ANKRD1, DUSP1,
FHL2) were selected for further quantitative RT-PCR anal-
ysis (Table 2). The reason for this selection was that the
differential expressions of these genes had the potential to
influence the anticancer effects of colchicine on gastric
cancer cells. There was a good consistency between the
results of quantitative RT-PCR and microarray. Colchicine
caused a dose-dependent upregulation of ANKRD1 in both
cell lines and DUSP1 in ASG cells. Only 6 ng/mL colchicine
could upregulate DUSP1 in NCI-N87 cells and FHL2 in both
cell lines.
Nude mouse experiment
All mice survived. There was no significant change in body
weight during the treatment period between the
colchicine-treated mice and the control mice (1  0.58 g vs.
1.14  0.38 g, p Z 0.59). After 14 days of treatment, the
increased tumor volume ratios in the colchicine-treated
mice were significantly lower than in the control mice
(p Z 0.0199; Figure 2). After 14 days of treatment, the
tumor growth rates in the colchicine-treated mice wereTable 2 Gene expression fold change caused by colchicine in t
Gene name ANKRD1
Colchicine (ng/mL) 2/0a 6/0 6/2 2/
ASG 1.43 3.48 2.43 1.3
NCI-N87 1.38 4.24 3.05 1.1
Gene expression fold change was determined by quantitative reverse
TBP (TATA box binding protein) was used as reference gene. A gene
downregulation.
a The values in this row are presented as colchicine concentration
cells.significantly lower than in the control mice (0.062  0.013/
d vs. 0.081  0.014/d, p Z 0.024).
Discussion
The present in vitro study showed that the antiproliferative
effects of colchicine on gastric cancer cells were achieved
only at concentration of 6 ng/mL. These results were
different from our previous studies in which 2 ng/mL
colchicine already had significant antiproliferative effects
on hepatocellular carcinoma cells and cholangiocarcinoma
cells [16,17]. This indicates that different kinds of cells
have different susceptibility to colchicine cytotoxicity.
Apart from the well-known direct colchicineetubulin
interaction to perturb the assembly dynamics of microtu-
bules as the common anticancer mechanism of colchicine
[8e12], the different influence of colchicine on differential
expressions of genes among different cell types may
contribute to a different susceptibility to colchicine.
Several differentially expressed genes that may contribute
to the colchicine anticancer effects on hepatocellular car-
cinoma cells (upregulated: AKAP12, TGFB2; down-
regulated:C4BPA, SEPP1 [16]) and cholangiocarcinoma cellshe ASG and NCI-N87 cell lines.
DUSP1 FHL2
0 6/0 6/2 2/0 6/0 6/2
8 3.63 2.63 1.16 2.16 1.86
1 2.58 2.32 1.07 1.96 1.83
transcriptase-polymerase chain reaction. The housekeeping gene
expression fold change value 1.3 is upregulation and 0.7 is
in the experimental cells/colchicine concentration in the control
Figure 2. Increased tumor volume ratios in the colchicine-
treated mice and the control mice. The increased tumor vol-
ume ratio is Vx/V0 (in which Vx is the tumor volume at day x and
V0 is the baseline pretreatment tumor volume). Data are
expressed as the mean value  standard error of the mean
(i.e., error bars). The increased tumor volume ratios in
colchicine-treated mice after 14 days of treatment are signif-
icantly lower than in the control mice. (a) p Z 0.0199, based
on the unpaired t test.
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observed in gastric cancer cells. Among the consistently
differentially expressed genes induced by 6 ng/mL colchi-
cine in both gastric cancer cell lines, only one upregulated
gene (DUSP1) has the possibility to exert antiproliferative
effects on these cells. The protein encoded by DUSP1 be-
longs to the dual-specificity phosphatases family which can
dephosphorylate two types of residues: threonine and
tyrosine. The function of these phosphatases is to dephos-
phorylate and therefore inactivate the mitogen-activated
protein (MAP) kinases [24]. Upregulation of DUSP1 leads
to the suppression of extracellular signal-regulated kinase
(ERK) [24e26], S-phase kinase-associated protein 2/CDC28
protein kinase 1B ubiquitin ligase complex [25], and thus
the inhibition of cellular proliferation [24e26] and the in-
duction of apoptosis [25]. Colchicine at concentration of
2 ng/mL only slightly upregulated DUSP1 in the ASG cell line
but had no effect on the NCI-N87 cell line. This finding may
be a possible explanation for the non-anticancer effect of
2 ng/mL colchicine in both cell lines.
Colchicine at concentration of 6 ng/mL also concomi-
tantly induced differential expressions of eight genes,
which have the potential to promote the proliferation of
cancer cells. These included upregulated ANKRD1 [27,28],
CTGF [29,30], EDN1 [31,32], KRT14 [33], KRT17 [34], NCF2
[35,36] genes, and downregulated DUSP9 [37,38] and
ZNF652 [39,40] genes. However, these adverse effects can
be overcome by direct colchicineetubulin interaction and
upregulated DUSP1 evidenced by our results from the
in vitro and in vitro studies. For the other differentially
expressed genes, four genes (upregulated: FHL2, GBP1,
TGFBI; downregulated: FZD9) have controversial effects on
the proliferation of cancer cells, and the remaining 15
genes have unknown effects on cellular proliferation.
In conclusion, colchicine has the potential for the
palliative treatment of gastric cancer. However, this anti-
cancer effect is achieved only at high clinically acceptablecolchicine concentrations. Monitoring the colchicine
plasma concentration is mandatory if this drug is applied
for the palliative treatment of gastric cancer.
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